Mar 3, 2026 05:31PM
Jan 6, 2026 08:00AM
Dec 12, 2025 11:00AM
Dec 12, 2025 11:00AM
Nov 10, 2025 04:05PM
Nov 7, 2025 06:10PM
Oct 21, 2025 08:00AM Mineralys to present Phase 2 CKD trial data at ASN Kidney Week 2025
Oct 21, 2025 08:00AM
Sep 30, 2025 08:01AM
Sep 30, 2025 08:00AM
Sep 8, 2025 07:13AM
Sep 5, 2025 09:00AM
Sep 5, 2025 09:00AM
Aug 12, 2025 04:05PM Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 14, 2025 08:20AM
Jun 30, 2025 11:19AM
Jun 30, 2025 11:17AM
Jun 18, 2025 06:44AM
Jun 17, 2025 07:00AM
Jun 17, 2025 07:00AM
May 24, 2025 04:30AM Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension
May 20, 2025 08:01AM
May 20, 2025 08:00AM
May 12, 2025 04:05PM
Apr 23, 2025 05:25PM
Apr 23, 2025 05:23PM
Mar 29, 2025 02:30PM
Mar 17, 2025 08:00AM Mineralys Therapeutics (MLYS) Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat
Mar 17, 2025 08:00AM
Mar 10, 2025 07:01AM
Mar 10, 2025 07:00AM
Feb 12, 2025 07:00AM
Feb 4, 2025 08:06AM
Feb 4, 2025 08:00AM
Jan 8, 2025 08:06AM Mineralys Therapeutics (MLYS) Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Jan 8, 2025 08:00AM
Nov 11, 2024 04:05PM
Oct 30, 2024 08:00AM
Oct 22, 2024 08:00AM
Sep 25, 2024 08:00AM
Aug 14, 2024 05:52AM
Aug 13, 2024 04:05PM Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Jun 14, 2024 08:01AM
Jun 14, 2024 08:00AM
May 9, 2024 07:00AM
Mar 21, 2024 07:00AM
Jan 4, 2024 04:05PM
Jan 4, 2024 04:05PM
Dec 21, 2023 04:05PM Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Nov 11, 2023 11:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All